Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Safety and efficacy of IL-12 plasmid DNA transfection into pig skin : supportive data for human clinical trials on gene therapy and vaccination
Avtorji:ID Lampreht Tratar, Urša (Avtor)
ID Jesenko, Tanja (Avtor)
ID Omerzel, Maša (Avtor)
ID Seliškar, Alenka (Avtor)
ID Stupan, Urban (Avtor)
ID Djokić, Mihajlo (Avtor)
ID Sredenšek, Jerneja (Avtor)
ID Trotovšek, Blaž (Avtor)
ID Serša, Gregor (Avtor)
ID Čemažar, Maja (Avtor)
Datoteke:URL URL - Izvorni URL, za dostop obiščite https://www.mdpi.com/1422-0067/25/6/3151
 
.pdf PDF - Predstavitvena datoteka, prenos (16,83 MB)
MD5: F61407EF65A3DEE02520CB25A3B9E701
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Povzetek:Gene electrotransfer (GET) of plasmids encoding interleukin 12 (IL-12) has already been used for the treatment of various types of tumors in human oncology and as an adjuvant in DNA vaccines. In recent years, we have developed a plasmid encoding human IL-12 (phIL12) that is currently in a phase I clinical study. The aim was to confirm the results of a non-clinical study in mice on pharmacokinetic characteristics and safety in a porcine model that better resembled human skin. The GET of phIL12 in the skin was performed on nine pigs using different concentrations of plasmid phIL12 and invasive (needle) or noninvasive (plate) types of electrodes. The results of our study demonstrate that the GET of phIL-12 with needle electrodes induced the highest expression of IL-12 at the protein level on day 7 after the procedure. The plasmid was distributed to all tested organs; however, its amount decreased over time and was at a minimum 28 days after GET. Based on plasmid copy number and expression results, together with blood analysis, we showed that IL-12 GET is safe in a porcine animal model. Furthermore, we demonstrated that pigs are a valuable model for human gene therapy safety studies.
Ključne besede:interleukin 12, gene electrotransfer, immunotherapy
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Poslano v recenzijo:27.11.2023
Datum sprejetja članka:06.03.2024
Datum objave:09.03.2024
Založnik:MDPI
Leto izida:2024
Št. strani:str. 3151-1-3151-12
Številčenje:Vol. 25, no. 6
Izvor:Basel, Switzerland
PID:20.500.12556/DiRROS-18738 Novo okno
UDK:602
ISSN pri članku:1422-0067
DOI:10.3390/ijms25063151 Novo okno
COBISS.SI-ID:191795459 Novo okno
Avtorske pravice:by Authors
Opomba:Nasl. z nasl. zaslona; Opis vira z dne 9. 4. 2024;
Datum objave v DiRROS:18.04.2024
Število ogledov:58
Število prenosov:34
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:International journal of molecular sciences
Skrajšan naslov:Int. j. mol. sci.
Založnik:MDPI
ISSN:1422-0067
COBISS.SI-ID:2779162 Novo okno

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:09.03.2024

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:interlevkin 12, elektroprenos genov, imunoterapija


Nazaj